{"id":"ag10-oral-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral edema"},{"rate":null,"effect":"Dyspnea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AG10 is a transthyretin stabilizer that binds to the TTR protein and increases its thermodynamic stability, preventing dissociation into monomers that would otherwise misfold and aggregate into amyloid fibrils. By stabilizing the native TTR tetramer, AG10 halts the pathological cascade underlying transthyretin amyloidosis, particularly in the cardiac form of the disease.","oneSentence":"AG10 stabilizes transthyretin (TTR) protein to prevent its misfolding and aggregation, which causes amyloid deposition in cardiac and neurological tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:00:17.487Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Transthyretin cardiac amyloidosis (ATTR-CM), wild-type and hereditary forms"}]},"trialDetails":[{"nctId":"NCT04958135","phase":"PHASE1","title":"Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2021-05-30","conditions":"Healthy","enrollment":18},{"nctId":"NCT06563895","phase":"PHASE3","title":"Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant","status":"RECRUITING","sponsor":"Eidos Therapeutics, a BridgeBio company","startDate":"2025-05-12","conditions":"Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis","enrollment":582},{"nctId":"NCT03294707","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10","status":"COMPLETED","sponsor":"Eidos Therapeutics, a BridgeBio company","startDate":"2017-09-11","conditions":"Amyloid Cardiomyopathy, Transthyretin-Related","enrollment":56},{"nctId":"NCT04418024","phase":"PHASE3","title":"Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy","status":"WITHDRAWN","sponsor":"Eidos Therapeutics, a BridgeBio company","startDate":"2020-10-21","conditions":"Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy","enrollment":""},{"nctId":"NCT04882735","phase":"PHASE3","title":"Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)","status":"WITHDRAWN","sponsor":"Eidos Therapeutics, a BridgeBio company","startDate":"2021-09-08","conditions":"Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy","enrollment":""},{"nctId":"NCT03860935","phase":"PHASE3","title":"Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy","status":"COMPLETED","sponsor":"Eidos Therapeutics, a BridgeBio company","startDate":"2019-03-19","conditions":"Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis","enrollment":632},{"nctId":"NCT03458130","phase":"PHASE2","title":"Study of AG10 in Amyloid Cardiomyopathy","status":"COMPLETED","sponsor":"Eidos Therapeutics, a BridgeBio company","startDate":"2018-04-27","conditions":"Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM)","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eidos Therapeutics AG10","TTR Stabilizer","Oral AG10"],"phase":"phase_3","status":"active","brandName":"AG10 oral tablet","genericName":"AG10 oral tablet","companyName":"Eidos Therapeutics, a BridgeBio company","companyId":"eidos-therapeutics-a-bridgebio-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AG10 is an oral tablet used in clinical trials for conditions such as Familial ATTR-CM, Wild-type ATTR-CM, and Amyloid Cardiomyopathy. AG10 is a biological vaccine that induces an immune response, according to its mechanism of action.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}